Related Experiment Video
Updated: Jul 15, 2026
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
Bone marrow stem cell therapy for myocardial angiogenesis
Hung-Fat Tse1, Kai-Hang Yiu, Chu-Pak Lau
1Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China. hftse@hkucc.hku.hk
Insights
Adult bone marrow stem cells show promise for treating coronary artery disease (CAD) by improving heart function through neovascularization. Further research is needed to clarify optimal strategies and long-term outcomes for this therapy.
Area of Science:
- Cardiology
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Coronary artery disease (CAD) is a leading cause of death globally, particularly in developing nations.
- Severe CAD leads to myocardial ischemia, cardiomyocyte loss, and heart failure, necessitating novel therapeutic strategies.
- Adult bone marrow (BM)-derived stem cells have shown potential for inducing neovascularization and improving cardiac function in experimental models.
Purpose of the Study:
- To investigate the potential of adult bone marrow stem cell transplantation for treating severe coronary artery disease (CAD).
- To explore the therapeutic angiogenesis and myocardial regeneration capabilities of bone marrow-derived stem cells in ischemic heart conditions.
Main Methods:
- Review of experimental studies and initial clinical trials on bone marrow stem cell therapy for heart disease.
- Discussion of challenges in stem cell identification, purification, and expansion for myocardial regeneration.
Main Results:
- Experimental studies indicate that bone marrow stem cells can promote neovascularization in ischemic myocardium and improve heart function.
- Early clinical trials suggest potential benefits of bone marrow therapy for therapeutic angiogenesis in CAD patients.
Conclusions:
- Bone marrow stem cell therapy presents a promising approach for managing refractory heart diseases, including CAD.
- Further rigorously designed, randomized clinical trials are essential to establish the long-term safety, optimal timing, and treatment strategies for bone marrow-derived stem cell therapy in CAD.
Abstract:
Despite the recent advances in medical therapy and coronary revascularization procedures, coronary artery disease (CAD) remains the major cause of morbidity and mortality in the developing countries. In patients with severe CAD, persistent myocardial ischemia in hibernated myocardium resulted in progressive loss of cardiomyocytes with development of heart failure. As a result, therapeutic approaches to enhance neovascularization are being underwent intensive investigation. Recent experimental studies have demonstrated adult bone marrow (BM) can induce neovascularization in ischemic myocardium can improve heart function. These findings have prompted the development of different cellular transplantation approaches for heart diseases refractory to conventional therapy after myocardial infarction. Although the initial pilot clinical trials have shown potential clinical benefit of BM therapy for therapeutic angiogenesis, the long-term safety, the optimal timing and treatment strategy remains unclear. Furthermore, in order to acquire more optimized quality and quantity of BM derived stem cell for myocardial regeneration, several issues remain to be addressed, such as the development of a more efficient method of stem cells identification, purification and expansion. Emerging, rationally designed, randomized clinical trials are required to assess the clinical implication of BM derived stem cells therapy in treatment of CAD.
